Topics:

Analyst: Ebola vaccine developers 'need to weigh risks' as cases dwindle

Tools
Ebolavirus under an electron microscope--Courtesy of CDC

The number of Ebola cases in West Africa has been declining, which has made it more difficult to enroll patients for clinical trials of leading vaccine candidates. And the way GlobalData analyst Daian Cheng sees it, that means it's time for vaccine manufacturers to "weigh the risks and benefits of developing further interventions for a disease that goes through unpredictable cycles of intense outbreaks followed by its virtual disappearance." Release

Filed Under

Comments